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Abstract
Antimicrobial use in food animals may contribute to antimicrobial resistance in bacteria of animals and humans. Commensal
bacteria of animal intestine may serve as a reservoir of resistance-genes. To understand the dynamics of plasmid-mediated
resistance to cephalosporin ceftiofur in enteric commensals of cattle, we developed a deterministic mathematical model of
the dynamics of ceftiofur-sensitive and resistant commensal enteric Escherichia coli (E. coli) in the absence of and during
parenteral therapy with ceftiofur. The most common treatment scenarios including those using a sustained-release drug
formulation were simulated; the model outputs were in agreement with the available experimental data. The model
indicated that a low but stable fraction of resistant enteric E. coli could persist in the absence of immediate ceftiofur
pressure, being sustained by horizontal and vertical transfers of plasmids carrying resistance-genes, and ingestion of
resistant E. coli. During parenteral therapy with ceftiofur, resistant enteric E. coli expanded in absolute number and relative
frequency. This expansion was most influenced by parameters of antimicrobial action of ceftiofur against E. coli. After
treatment (.5 weeks from start of therapy) the fraction of ceftiofur-resistant cells among enteric E. coli, similar to that in the
absence of treatment, was most influenced by the parameters of ecology of enteric E. coli, such as the frequency of transfer
of plasmids carrying resistance-genes, the rate of replacement of enteric E. coli by ingested E. coli, and the frequency of
ceftiofur resistance in the latter.
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Introduction
The emergence and spread of antimicrobial resistance (AMR) is
progressively demarcating the epochal success of antimicrobial
therapies of bacterial infections. Some classes of antimicrobials are
used in both human and veterinary medicines; among antibiotics
these are b-lactams, including cephalosporins, as well as amino-
glycosides, macrolides, tetracyclines, sulphonamides, and in some
countries fluoroquinolones [1]. Humans may be exposed to AMR-
bacteria from food animals via occupational exposure or
contaminated food products. In the 1990s in the USA, a
domestically-acquired infection of a boy with ceftriaxone-resistant
Salmonella was traced to cattle carrying ceftiofur-resistant Salmonella
after the boy’s father had treated the diarrheic calves [2]. Human
food-borne infections with AMR-bacteria are clinically challeng-
ing [1,3]. Furthermore, ingested strains can become a part of the
human enteric microflora [4], and transmit AMR-genetic
determinants to other human bacteria [5]. For cephalosporins,
the principal mechanism via which resistance disseminates is
horizontal transfer of AMR-genes encoded on conjugative
plasmids [6,7,8]. The AMR-strains occasionally demonstrate a
higher transmissibility via the food chain, e.g., an AMR-strain of
Escherichia coli (E. coli) on pig carcasses has survived processing and
chilling better than the parental antimicrobial-sensitive strain [9].
Cattle meat products can be contaminated by animals’ feces, and
so the enteric microflora [10]. Therefore, minimizing the
frequency of AMR in cattle enteric bacteria en masse can aid in
decreasing human exposure to AMR-strains.
Within animal hosts, enteric commensals may also transmit
AMR-genetic determinants to pathogens, e.g., E. coli can transmit
plasmidic AMR-genes to Salmonella [11,12]. However, the in-vivo
frequency of such transfer is unknown, and may be limited by the
number of plasmids shared [12], differences in plasmid develop-
ments between bacterial species [11], or restrictions on plasmid
establishment in the heterologous recipients [13]. The frequency
of plasmid transfer from E. coli to Salmonella is much lower
compared to promiscuous plasmid sharing between E. coli cells
[12]. However, occasionally AMR-strains themselves exhibit a
higher virulence for [14], or a greater ability to colonize animal
hosts [15,16]. This necessitates the use of even newer drugs to
combat animal infections [1].
A complete cessation of antimicrobial therapies in food animals
is impractical [1], and, in the absence of alternatives, unethical
[17]. The real challenge is to implement therapies that minimize
emergence and spread of AMR [17,18]. Also, farm animals
present a model system where the potential of candidate policies
for reduction of antimicrobial usage can be evaluated at the
population level, with further relevance to policies in humans [19].
The containment of resistance to 3rd generation cephalosporins
is categorized by the World Health Organization as critically
important. Ceftiofur is the only drug in this class licensed to treat
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that of ceftriaxone, which is used to treat bacterial meningitis and
salmonellosis in humans. Ceftiofur is administered parenterally to
individual cattle to treat interdigital necrobacillosis, pneumonia or
metritis, and to groups of beef calves for metaphylaxis of bovine
respiratory disease (BRD). The drug can also be applied
intramammary to treat mastitis or as a dry-off therapy.
Resistance to ceftiofur in enteric bacteria of cattle in the USA is
mediated predominantly by plasmid-encoded gene blaCMY-2
[12,20], which codes for a cephamycinase [21,22,23]. The gene
has been reported in Salmonella and E. coli isolates from feces of
food animals and meat products in retail [24], and in Salmonella
isolates responsible for human illness [25,26]. The resistant E. coli
have been isolated from feces of beef and dairy cattle, sewage and
ground beef [24,27]. Between bacteria, both inter-generational
and horizontal transfers of plasmidic blaCMY-2 occur. In the
enteric environment, the horizontal plasmid transfer is the main
mechanism of AMR-gene spread within and between bacterial
species, both Gram-positive and Gram-negative [13]. E. coli can
constitute up to 86% of the fecal Gram-negative bacteria in dairy
cattle [28], and act as a donor of plasmidic AMR-genes [13].
Recent field studies demonstrate that a fraction of enteric E. coli
carry plasmidic blaCMY-2 even in cattle not known to be treated
with ceftiofur [27,29,30]. Enteric E. coli are primarily commensal
and are genetically diverse [10,31]; among them, E. coli carrying
blaCMY-2 are not strongly clonal at either serotype or PFGE levels
[6,12]. The ‘‘background’’ resistant fraction can have mixed
origins. Ecological origins may include adaptation of bacteria to
co-exist with fungi that are natural producers of b-lactams, and
subsequent transfer of chromosomal AmpC locus from Citrobacter
freundii to other Enterobacteriaceae as a plasmidic gene [21,32]. Also,
exposure to resistant E. coli can occur on the farm when post-
weaned calves are colonized with ruminant-specific microflora
(Tom Besser, personal communication). Similarly, ceftiofur-
resistant E. coli in broilers is associated with its presence at the
hatchery and on the farm [33].
During parenteral treatment with ceftiofur, a decline in the
numbers of enteric E. coli is reported in healthy 3-4 mos old calves
[27], healthy adult cattle [34], and lactating dairy cattle treated for
metritis or interdigital necrobacillosis [35] (Table S1). Studies
employing genetic methods to examine the effects on entire enteric
bacterial populations have arrived at similar conclusions [36]. This
strongly suggests that parenteral treatment of cattle with ceftiofur
results in exposure of their enteric bacteria to antimicrobially-
active drug metabolites, with the dose and duration sufficient for
prominent effects on the enteric bacteria.
The objectives of this modeling study were to analyze, first,
whether the reported fractions of blaCMY-2-carrying commensal
enteric E. coli in cattle could be maintained in the absence of
immediate ceftiofur pressure; and, second, how the dynamics of
the resistant and sensitive enteric E. coli changed during parenteral
ceftiofur treatment depending on the treatment protocol.
Materials and Methods
Dynamics of Ceftiofur-sensitive and Resistant
Commensal Enteric E. coli in the Absence of Immediate
Ceftiofur Pressure
Ecology of commensal enteric E. coli. A flow-chart of the
model is given in Figure 1. Due to unfavorable conditions for E.
coli growth in the upper parts of the cattle gastrointestinal tract,
only E. coli in the large intestine was considered (referred to as
‘‘commensal enteric E. coli’’). These may exist in a planktonic
‘‘free-living’’ mode of growth, or by being incorporated into
intestinal biofilms [37]. The biofilm-trapped latter likely constitute
a small fraction of the total, hence enteric E. coli were considered
to be free-living. Population growth of E. coli, as a facultative
anaerobe, slows in anaerobic conditions [38]; the maximum net
growth rate (in exponential growth phase) in numbers of enteric E.
coli, r, was parameterized accordingly. E. coli growth in the enteric
environment is likely further restricted by intra-specific competi-
tion, inter-specific competition with other microflora, and feces
substrate composition [39]. A logistic model of bacterial growth
was used to reflect the intra-specific competition. The upper limit
for total E. coli per g of feces, Nmax, was parameterized from the
reported numbers of viable E. coli in cattle feces (Table 1), and so
bore the expected effects of the inter-specific competition.
E. coli is capable of replicating outside animal hosts; commensal
E. coli circulate between cattle hosts and their environment [40]. In
beef cattle reared at either pasture or feedlot, ,60% of fecal E. coli
are genetically related to those in animals’ oral cavities [31]. From
in vivo experiments in post-weaned calves [27], an estimated ,20–
30% of fecal coliforms are E. coli strains fed to the animals on the
day of measure or the preceding day. The in-flow of ingested
bacteria and the out-flow of bacteria with feces likely ensures a
regular partial replacement of E. coli ‘‘free-living’’ in the large
intestine. To reflect this, the rates of hourly fractional in-flow and
outflow of enteric E. coli were taken to be equal, both c. A fraction
u of the ingested bacteria was assumed to carry plasmids with
blaCMY-2. In-flowing bacteria would mix homogeneously with
those already in the intestine.
Plasmid transfer and fitness cost of plasmid-mediated
resistance. Various conjugative plasmids of E. coli can carry
blaCMY-2 [12]. There is no evidence of enhanced plasmid transfer
in enteric E. coli during parenteral ceftiofur therapy [27]. The
maximum number of cells to which a donor E. coli can transfer a
plasmid per unit time is inherently restricted by biology of
conjugation; the transconjugant (recipient cell) undergoes a 40-80
minutes maturation before becoming a proficient donor [41].
Therefore, the transfer was modeled as a contagious process
[65,66] with frequency-dependent transmission. b was the
transmission term for blaCMY-2-carrying plasmids from resistant
donor to sensitive cells, Nr - number of resistant cells, Ns - number
of sensitive cells, and N - total number of E. coli cells. Then, ‘‘force
of transfer’’ per a sensitive cell per unit time was b*Nr/N, and the
total transfer was b*Nr*Ns/N.
The growth rate of a bacterial strain is considered to represent
its evolutionary fitness [38]. Having blaCMY-2-carrying plasmids is
associated with either a fitness cost, i.e., reduced growth [42], or a
fitness gain, i.e., enhanced growth [43]; or no change in growth
[44]. The fitness cost appears more often, and was modeled as a
fractional reduction, a, in net growth rate, r [45].
The fate of AMR-bacterial strains in the absence of antimicro-
bial pressure is unclear. In some laboratory experiments, a gradual
loss of AMR-gene-carrying plasmids during cell divisions after
thousands of bacterial generations (several months) is reported
[42]; others, however, report maintenance of the plasmid profile,
in particular by E. coli [44]. The AMR-strains can acquire
compensatory mutations to restore fitness without losing resis-
tance, e.g., a better growth performance of E. coli with chromo-
somal-encoded resistance to streptomycin [46], or plasmid-
encoded resistance to tetracycline [43]. Notably, these processes
occur over extended time horizons. The period of parenteral
treatment of cattle with ceftiofur is at most 7 days, followed by at
most a 13-day pre-slaughter withdrawal period. Hence the
possibility of loss of plasmidic blaCMY-2 by enteric E. coli was
not considered in this analysis.
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differential Equations [1] and [2] described the changes in Ns and
Nr, respectively, over time in the absence of immediate ceftiofur
pressure:
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Dynamics of Ceftiofur-sensitive and Resistant
Commensal Enteric E. coli During Parenteral Ceftiofur
Treatment
Pharmacokinetics and biodegradation of ceftiofur
metabolites. Ceftiofur in cattle is metabolized shortly post
injection (p.i.) [47]. Major ceftiofur metabolites retain the b-lactam
ring [48]; their antimicrobial activity against E. coli is close to that
of ceftiofur [49,50]. The total of ceftiofur and its active metabolites
is termed the concentration of ceftiofur equivalents (CE) [51]. The
pharmacokinetics of ceftiofur in cattle following an intramuscular
(IM) or a subcutaneous (SC) injection in cattle are similar in terms
of CE-pattern in the plasma [52]. The pharmacokinetics of
formulations containing ceftiofur sodium and ceftiofur hydrochlo-
ride salts are similar in terms of CE-pattern in the plasma of pigs
[53]; this is considered to hold for cattle [48].
In humans, ceftriaxone (its structure is close to that of ceftiofur)
is excreted via both renal and hepatic pathways [54]. There is no
evidence of a correlation between ceftriaxone concentrations in
bile (bile metabolite is structurally similar to ceftriaxone) and in
plasma [54], or of ceftriaxone intestinal absorption and enterohe-
patic circulation [55]. The rate of ceftriaxone biliary excretion in
humans positively correlates with the rate of bile acid secretion
[56]; experimental data in rats suggest a common mechanism for
hepatic transport of ceftriaxone and bile acids [57]. There is inter-
individual variability in achieved ceftriaxone concentrations in bile
[54,56,58], and in feces [54] of humans.
In cattle, ceftiofur administered parenterally is also excreted via
both urine (,65%) and, through bile, feces (,35%) [47]. There
are no published data on the pattern or inter-individual variability
of the biliary excretion. We assumed that in cattle, as in humans,
there was no enterohepatic ceftiofur circulation, and CE-
concentration in the intestine was independent of that in
systematic distribution. Of (radio-labeled) ceftiofur dose injected
IM, 29% is detected in cattle feces in 8 hours, and 37% in 12
hours p.i. [51]. The exact structure of intestinal metabolites is
unknown; although it is likely that they enter the large intestine
having an intact b-lactam ring. However, most of the (radio-
labeled) amounts in feces lack antimicrobial activity [48,59]. This
Figure 1. Flow-chart of the model of the dynamics of ceftiofur-sensitive and resistant commensal E. coli in the cattle large intestine.
Bacterial growth is density-dependent with fractional net growth rate r; fitness cost for cells with blaCMY-2-carrying plasmids manifests as a reduction
a in r. Resistant cells transfer blaCMY-2 to the progeny during cell division. Horizontally, blaCMY-2 is transferred to the sensitive cells at rate b; the
transmission is frequency-dependent with the total of b*Nr*Ns/N. There is fractional in-flow and out-flow of E. coli at rate c; fraction u of in-flowing E.
coli are ceftiofur-resistant. Antimicrobial action of ceftiofur metabolites, depending on their concentration, results in either reduced growth or decay
in number of E. coli.
doi:10.1371/journal.pone.0036738.g001
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and outside the intestinal environment [60], because of variable
timing of metabolite degradation in normal vs. sterilized cattle
feces [60]. In normal cattle feces fortified with 100 mg/g of CE,
under aerobic conditions it takes ,8 hours for these to entirely
degrade to antimicrobially inactive compounds [48,60]. The
dynamics of decline in CE-concentration appears to be an
exponential decay [48,60]. The exact enteric species producing
b-lactamases involved are unknown [48]; different species may be
involved, as plasmid-mediated b-lactamases are widely produced
by Gram-negative bacteria [61].
Let D denote ceftiofur dose in one injection. Fraction p of D was
excreted in bile, and the volume of the animal’s large intestine
was V.
First consider a therapy with repeated injections of a non-
sustained-release ceftiofur formulation (Table S1, scenarios R1-
R3). D was, and p and V were taken to be equal for every injection
nj, which occurred at time Tj since start of treatment, t=0. As the
pattern of ceftiofur biliary excretion is unknown, two possibilities
were explored. Under pattern 1, amount D*p was excreted at 1
hour p.i. After a passage time Td, biliary metabolites entered the
large intestine. At entry, for a given nj, CE-concentration per g of
feces (assuming weight-to-volume ratio of feces of 1) was D*p/V,
then decayed exponentially due to the biodegradation at rate l.
Total CE-concentration per g of feces in large intestine, C (CE mg/
g), at time t was:
Ct ðÞ ~
Pn
j~1 cj(t) ð3Þ
cj(t)~
0; tvTjz1zTd
Dp
V exp {l t{(Tjz1zTd) ðÞ ðÞ ; t§Tjz1zTd
(
ð4Þ
where Tj~24(nj{1); j=injection number: 1, …, n, n=5
Under pattern 2, m=6 equal fractions of D*p were excreted
hourly at hour 1 to 6 p.i. (similarly to uniform patterns of
ceftriaxone biliary excretion in rabbits [62], and of bile flow in
Table 1. Parameter definitions and values.
Parameter Definition, units Value Reference
Bacteria
r Specific growth rate, h
21 0.17 estimated from [39]
c Fractional in-flow/out flow, h
21 0.01 estimated from [27]
Nmax Max E. coli, log CFU/g of feces
6-mos beef (220 kg) 5.5 [31]
6-mos dairy (180 kg) 6.5 [27]
adult dairy (600 kg) 4.3 [90]
post-partum/lactating dairy (600 kg) 4.3 –
AMR
pAMR Fraction of ceftiofur-resistant enteric E. coli at start of treatment
6-mos beef (220 kg) 0.018 [80]
6-mos dairy (180 kg) 0.050 [78]
adult dairy (600 kg) 0.007 [79]
post-partum/lactating dairy (600 kg) 0.018 –
b Plasmid transmission term, h
-1 0.004 [27,42]
a Resistance fitness cost as fraction of r 0.05 [42]
u Resistant E. coli fraction in in-flow
(pAMR*0.6 based on [31])
6-mos beef (220 kg) 0.0110
6-mos dairy (180 kg) 0.0310
adult dairy (600 kg) 0.0042
post-partum/lactating dairy (600 kg) 0.0110
Biliary ceftiofur metabolites
p Bile-excreted fraction of injected dose 0.37 [47,51]
Td Passage time to large intestine, h 6 –
V Volume of large intestine, L
6-mos beef or dairy 5 –
adult cattle 20 –
l Biodegradation decay constant, h
21 0.2 estimated from [48,60]
H Hill coefficient in Emax model 1.5 estimated using [68]
MICs MIC for sensitive E. coli, mg/mL 1 –
MICr MIC for resistant E. coli, mg/mL 8 –
doi:10.1371/journal.pone.0036738.t001
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1 to 6 p.i. was based on the working hypothesis that Td=6 hours,
thus the entire amount D*p would reach the large intestine by 12
hours p.i (as in experimental observations [51]). Initial CE mg/g
feces was D*p/6*V. The concentration C (CE mg/g), at time t was
as in Equation [3]; c
j for a given nj was:
cj(t)~
Pm
k~1 ck(t) ð5Þ
Figure 2. Pharmacodynamic model. A. Multiplicative pharmacodynamic effect on E. coli net growth with a constant minimum inhibitory
concentration (MIC=1 mg/mL) and changing ceftiofur concentration expressed as multiples of MIC; Hill coefficient=1.5. B: Multiplicative
pharmacodynamic effect on E. coli net growth with changing MIC and a constant ceftiofur concentration; Hill coefficient=1.5.
doi:10.1371/journal.pone.0036738.g002
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8
<
:
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where Tj~24(nj{1), j=injection number: 1, …, n, n=5 and
k=1,…m, m=6.
Now consider a SC injection of a sustained-release ceftiofur
formulation (Table S1, scenarios SB1-SB3 and SD1). According to
the data published by the drug manufacturer, plasma CE-
concentration peaks at hours 1 to 2 p.i., then declines but remains
above the therapeutic threshold (0.2 mg/mL) for ,10 days
[64,65]. Due to the quality of these data, data for 60 time points
over 10 days p.i. were extracted to detail the plasma pattern. We
assumed that the plasma pattern paralleled the pattern of drug
release, and that entire drug dose, D, was released within 10 days
p.i. At each time point i, amount di of ceftiofur (so that Pn~60
i~1 di~D; what fraction of D was di was determined by the
drug release pattern) was released at the site of injection. Fraction p
of di was excreted in bile 1 hour later. The passage of metabolites
to the large intestine, and decay in their concentration due to the
biodegradation were modeled similarly to the above.
Pharmacodynamic effect. Antimicrobial action of b-lac-
tams results in the death of growing, preparing to divide bacteria
(both the dividing cell and its ‘‘daughter’’ cell are killed);
unaffected growing cells replicate (survive and produce ‘‘daughter’’
cells) [66]. What fraction of growing cells is killed vs. is replicating
at a given time, and so what is net growth or decline of the
bacterial population, depends on the concentration of b-lactams
[67,68]. The changes in net growth of ceftiofur-sensitive and
resistant enteric E. coli depending on CE-concentration were
modeled using a fractional inhibitory Emax pharmacodynamic (PD)
model, where Emax term specifies the maximum possible PD-effect
[69,70]. The 50% PD-effect was with stationary concentration of
CE, at which half of the growing cells were replicating, and half
were killed (no net change in number of bacteria) [71]. In the case
of b-lactams, for a given drug and microbe, the stationary
concentration is close to a commonly measured minimum
inhibitory concentration (MIC) [71]. Therefore, in this PD-model
at a CE-concentration ,MIC, net population growth was positive
(as more growing cells were able to replicate than were killed). At a
CE-concentration .MIC, the population declined. The maxi-
mum decline was when all growing cells were killed; the
population declined at the rate of attempted growth. This was
specified by setting Emax=2 (giving -1 as the multiplier for growth
rate at a sufficiently high CE-concentration). If CE-concentration
rose further, the PD-effect saturated, as no more cells could be
killed than those growing to divide. The PD-model behavior is
illustrated in Figure 2. The total kill depended on how long CE-
concentration was at or above that producing maximum effect.
The model therefore depicted time-dependent PD of cephalospo-
rins [68,72,73], with a point of maximum effect (at a drug
concentration of low multiples of MIC) after which further
concentration rise does not enhance the rate of killing [68,72,74].
The model also accounted for that for antimicrobial resistance via
enzymatic deactivation that can be surmounted by a higher drug
dose, the change in antimicrobial activity against resistant bacteria
should be reflected as an increase in the drug concentration
producing the 50% PD-effect [75].
Denoting MICs for ceftiofur-sensitive and MICr for resistant E.
coli, Es in Equation [7] and Er in Equation [8] described fractional
changes in net growth of ceftiofur-sensitive and resistant E. coli,
respectively, at CE-concentration C:
Es~1{ EmaxCH
MICsHzCH ð7Þ
Er~1{ EmaxCH
MICrHzCH ð8Þ
where Emax=2, and H is Hill coefficient.
Postantibiotic effect, the period post exposure to antibiotic after
which surviving bacteria begin to multiply normally, in Gram-
negative bacilli after the majority of b-lactams is from none to brief
[68,76,77], and so was not considered.
Model for dynamics during treatment. The ordinary
differential Equations [9] and [10] described the changes in Ns
and Nr, respectively, over time of parenteral ceftiofur treatment:
dNS
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Post treatment, when ceftiofur metabolites had been eliminated
from the large intestine (C=0, Es=1, Er=1), the dynamics
reverted to Equations [1] and [2].
Parameterization
Table 1 details the parameters and their values. The maximum
number of E. coli per g of feces in large intestine, Nmax, was based
on reported numbers of viable fecal E. coli (colony-forming units,
CFU, of E. coli or fecal coliforms were considered as a
measurement of viable E. coli). Starting values of Ns and Nr were
calculated using N (set at 90% of Nmax), and pAMR - fraction of
ceftiofur-resistant E. coli at start of treatment. pAMR estimates
were adopted from tests of E. coli sensitivity at start of or without
connection to ceftiofur treatments. The available estimates varied
depending on cattle age and purpose: 6% of ceftriaxone-resistant
E. coli for breakpoint $16 mg/mL in 2-6 mos post-weaned dairy
calves (estimated from [78]); 7.4% of ceftiofur-resistant E. coli for
breakpoint $16 mg/mL in dairy cattle [28]; 0.7% of ceftazidime-
resistant coliforms for breakpoint $8 mg/mL across samples from
39 dairy herds [79]; and 1.8% of ceftazidime-resistant E. coli for
breakpoint $8 mg/mL in feedlot steers [80].
E. coli doubling time in the large intestine was assumed to be 4
hours [39]; hence hourly net growth rate in the exponential phase
of population growth (in bacteriological terms, the specific growth
rate), r, was 0.17. The fitness cost of resistance (fractional decrease
in r) was parameterized from in vitro competition assays between E.
coli strains carrying plasmids with blaCMY-2 and those that do not;
a crude average of experimental data a=0.05 was used [42].
Rates of horizontal transfer of individual plasmids with blaCMY-
2 in vitro vary from 10
28 to 10
23 [42,81]. In vivo in post-weaned
calves fed a donor and a recipient E. coli strains, the overall rate of
generation of blaCMY-2-transconjugates in fecal E. coli is 8
25 to
2
23 [27].
The rates of hourly fractional in-flow and out-flow of E. coli
‘‘free-living’’ in the large intestine, c=0.01 (to the daily total of
Effects of Ceftiofur on Cattle Gut Commensals
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calves [27]. The fraction of ceftiofur-resistant cells in in-flow was
set at 0.6*pAMR, based on 60% genetic similarity of E. coli in oral
cavities and in feces of beef cattle reared at either pasture or
feedlot [31].
Of parenteral ceftiofur dose, D, fraction p=0.37 was excreted in
bile within 6 hours p.i. (under excretion pattern 1 or 2) [51];
metabolites reached the large intestine in Td=6 hours post
excretion. Volume of the large intestine was 20L in an adult cattle,
and 5L in a 6-mos calf. The rate of exponential decay in CE-
concentration in the large intestine was twice lower compared to
feces under aerobic conditions [48,60].
As there are no published data from a time-kill experiment for
E. coli and ceftiofur, the PD-model was applied to reproduce the
data from in vitro time-kill experiments for E. coli and b-lactam
ticarcillin [68], and performed well; H of 1.5 performed optimally
for both concentrations below and above MIC. Under aerobic
conditions, ceftiofur and its major metabolites are highly active
against veterinary isolates of E. coli, with MIC50=0.25 mg/mL and
MIC90=0.50 mg/mL [50]. Decrease in activity under anaerobic
conditions appears to be limited (‘‘one 2-fold dilution’’ in vitro), but
the data are scarce. For the PD-model, MICs=1mg/mL and
MICr=8mg/mL were used.
Sensitivity of methods based on bacteriological culture to detect
a strain of E. coli in bovine feces is generally restricted to when
.100 CFU/g is present [82]. We processed model outputs, Ns and
Nr, to separate scenarios when ceftiofur-resistant E. coli likely would
not be detected by culturing the feces.
Model Solving, and Uncertainty and Global Parameter
Sensitivity Analysis
Solutions of the ordinary differential equations were approxi-
mated numerically using the fourth-order Runge–Kutta method
Figure 3. Effect of therapy with repeated ceftiofur administration on enteric E. coli in the deterministic case considered (r=0.17,
a=0.05, b=4
23, c=0.01; all h
21). A: Fraction of ceftiofur-resistant among E. coli. B: Total number of E. coli. C: Dynamics of ceftiofur-sensitive and
resistant E. coli in an adult dairy. D: Dynamics of ceftiofur-sensitive and resistant E. coli in a post-partum dairy. pAMR=frequency of resistance at start
of therapy.
doi:10.1371/journal.pone.0036738.g003
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Inc.; Harvard, MA, USA). In the deterministic analysis, first, for
each treatment scenario (Table S1), the model without treatment
(Equations [1] and [2]) was solved varying parameter values to
reproduce the reported pAMR (Table 1). Then concentration C,
and PD-effects Es and Er were calculated. These were introduced
into the model (Equations [9] and [10]) and the equations were
solved. The models were solved starting with total E. coli, N,a t
90% of Nmax.
The analysis of uncertainty and global parameter sensitivity of
the model outputs was conducted for the treatment scenarios R2
and SB2 (Table S1). Given the dynamics of ceftiofur metabolites in
the large intestine during therapy (section Pharmacokinetics and
biodegradation of ceftiofur metabolites above), the sensitivity analysis was
targeted at how the model outputs correlated with changes in the
parameters of ecology of enteric E. coli (r, a, b, c and u), and of
pharmacodynamics of the metabolites against E. coli (MICs, MICr
and H). A uniform distribution (U) was assumed for all, because of
the lack of knowledge of distributions of individual parameters.
The minimum and maximum values were specified based on the
literature review (all rates h
21): r,U(0.05, 0.5), a,U(20.2, 0.2),
b,U(10
25, 0.01), c,U(10
23, 0.02), u,U(10
25, 0.10),
MICs,U(0.2, 1.9), MICr,U(2, 16), and H,U(0.5, 4). For each
of the two treatment scenarios, 500 Monte Carlo simulations were
performed with Latin Hypercube sampling of each parameter
space at each time point over 90 days from start of therapy for the
model with treatment, and for 180 days for the model without
treatment. This was implemented in VensimH PLE Plus software.
The uncertainty in model outputs was explored graphically. The
sensitivity of model outputs to changes in values of each parameter
was evaluated with the Spearman correlation coefficient (r) [83].
Whether r was significantly different from zero was tested with a
Figure 4. Effect of therapy using a sustained-release ceftiofur formulation on enteric E. coli in the deterministic case considered
(r=0.17, a=0.05, b=4
23, c=0.01; all h
21). A: Fraction of ceftiofur-resistant among E. coli. B: Total number of E. coli. Dynamics of ceftiofur-
sensitive and resistant E. coli in a 6-mos beef treated with C: 6.6 mg CE/kg dosage, and D: 4.4 mg CE/kg dosage. pAMR=frequency of resistance at
start of therapy.
doi:10.1371/journal.pone.0036738.g004
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simulations as w, calculated as T~jrj
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
w{2
1{r2
r
and assumed to
follow a t-distribution with (w-2) degrees of freedom. If the test’s p-
value was #0.05, the correlation was considered as significant.
Results
Deterministic Analysis
Maintenance of ceftiofur resistance in commensal enteric
E. coli in the absence of immediate ceftiofur pressure. In
the model without treatment (Equations [1–2]), for every scenario
(Table S1) the reported pAMR could be reproduced with r=0.17,
a=0.05, b=4
23, c=0.01, and u=0.6*pAMR. (These parameter
values were used for the deterministic analysis of treatment
scenarios: Table 1). Nmax corresponded to the scenario, and had no
influence on the dynamics observed. pAMR was most sensitive to
b and u (or, if u was kept constant, to c). b.0.01 (somewhat
unrealistic, see the discussion below) allowed reproducing the
reported pAMR if there was no ceftiofur resistance among
ingested E. coli, u=0. In all the scenarios, the resulting Nr was over
100; hence, culture-based methods would likely detect the
presence of resistance.
Effects of parenteral ceftiofur therapy on commensal
enteric E. coli: repeated ceftiofur administration. Models
with both hypothesized biliary excretion patterns produced
outputs resembling experimental data (Table S1); thus, biliary
excretion of ceftiofur likely occurs within the first several hours p.i.
Further results and discussion refer to the model with excretion
pattern 2 (uniform excretion hourly at hour 1 to 6 p.i.).
Figure 5. Fraction of ceftiofur-resistant among enteric E. coli in long-term absence of ceftiofur pressure. A: Uncertainty: frequency
histogram for 500 model simulations with randomly varying parameters of bacterial ecology. B: Sensitivity: significant linear correlations (p-value
#0.05) between ranked-transformed values of the parameters of bacterial ecology and the fraction of resistance.
doi:10.1371/journal.pone.0036738.g005
Figure 6. Uncertainty in the fraction of ceftiofur-resistant among enteric E. coli during 90 days from start of therapy. Statistics are for
500 model simulations at each time point randomly varying parameters of bacterial ecology and pharmacodynamics. A: A 5-day repeated ceftiofur
administration to an adult dairy (frequency of resistance at start of therapy 0.7%). B: An injection of a sustained-release ceftiofur formulation to a6 -
mos beef (frequency of resistance at start of therapy 1.8%).
doi:10.1371/journal.pone.0036738.g006
Effects of Ceftiofur on Cattle Gut Commensals
PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e36738Effects of Ceftiofur on Cattle Gut Commensals
PLoS ONE | www.plosone.org 10 May 2012 | Volume 7 | Issue 5 | e36738For all the treatment scenarios, the model (Equations [9–10])
outputs showed a decrease in counts of total and of ceftiofur-
sensitive enteric E. coli, and a rise in the fraction of resistant among
E. coli during therapy, similar to experimental observations (Fig. 3
cf. Table S1, scenarios R1-R3). For a 5-day therapy in an adult
dairy, the model showed a decrease in total count from day 1, to a
minimum on day 3, remaining decreased until day 4, and then
returning to pre-treatment level on day 7 (Fig. 3B). The timing was
close to the results for an on-farm 5-day ceftiofur therapy reporting
fecal E. coli decreasing from day 1, to a minimum on day 6 (the
samples were not collected every day), returning to pre-treatment
level by day 9 (Table S1, R2). The maximum drop differed
between the model, ,1.05 log CFU/g, and the on-farm study,
estimated ,4.0 log CFU/g. However, the count change in the
model corresponded to a 91% reduction in number of E. coli. Also,
there may have been inter-individual variability in the count and
its dynamics in the cattle treated on-farm, but only average
numbers were reported. For a 5-day therapy in a 6-mos dairy, the
model output of a 0.66 log CFU/g drop in total E. coli resembled
well the field data of 0.5-1 log CFU/g drop in culturable fecal
bacteria in individual 2-6 mos calves [78] (Fig. 3B cf. Table S1,
R1). In both these scenarios, the total E. coli count dropped starting
from day 1 of therapy.
As total E. coli was composed of both ceftiofur-sensitive and
resistant cells, propagation of the latter offset the decline in total
count, but this took time. E.g, in an adult dairy the total E. coli
count was lowest on day 3 of therapy, dropping by 1.05 log CFU/
g (Fig. 3B); but the count of ceftiofur-sensitive cells was lowest on
day 4, dropping by 1.68 log CFU/g (Fig. 3C). These corresponded
to a 91% and 98% reduction in number of bacteria, respectively.
The fraction of resistant among E. coli peaked on day 4 (Fig. 3A).
At this point, resistant cells filled most of the ‘‘carrying capacity’’,
sensitive cells grew less and were less exposed to antimicrobial
action (hence no further reduction in sensitive counts). Similarly,
in a 6-mos calf the number of sensitive E. coli dropped to its
minimum and the fraction of resistant E. coli rose to its maximum
(Fig. 3A) the next day after the maximum drop in total E. coli
(Fig. 3B).
In cattle of a given age treated under a given protocol, the lower
was the initial frequency of resistance, pAMR, the larger was the
decline in total count of E. coli (Fig. 3B, R2 vs. R3) and of sensitive
E. coli (Fig. 3C vs. 3D) during therapy. However, the maximum
fraction of resistant among E. coli during therapy did not seem to
depend on pAMR in the range explored, peaking to 90-91% in
either an adult (pAMR=0.7%), post-partum (pAMR=1.8%), or
6-mos (pAMR=5.0%) dairy (Fig. 3A). Yet it took longer for the
fraction to completely return to pre-treatment level if this already
had been elevated, e.g., ,16 weeks in a 6-mos (pAMR=5.0%) cf.
,10 weeks in an adult (pAMR=0.7%) dairy.
Scenarios R1-R3 were repeated with ceftiofur dosage 1.1 mg
CE/kg (with biliary excretion pattern 1). In an adult dairy,
including post-partum, there was a slightly lesser peak in number
and relative fraction of resistant E. coli, and a day later in therapy
compared to using 2.2 mg CE/kg. There was however a
difference in a 6-mos dairy; the drop in total E. coli was 26%
with 1.1 mg vs. 64% with 2.2 mg dosage, and the fraction of
resistant cells rose to 27% vs. 80%, returning to pre-treatment level
in 104 vs. 110 days, respectively.
Effects of parenteral ceftiofur therapy on commensal
enteric E. coli: sustained-release ceftiofur
formulation. For a 6-mos beef administered a sustained-release
ceftiofur formulation, lowering the dosage to 4.4 from 6.6 mg CE/
kg (Table S1, SB3 vs. SB2), resulted in a smaller drop in total E.
coli, 1.11 vs.1.54 log CFU/g, occurring a day earlier, day 2 vs. day
3, of therapy (Fig. 4B). The count of sensitive E. coli dropped by
1.83 log CFU/g with 4.4 mg vs. by 2.4 log CFU/g with 6.6 mg
(98.5% vs. 99.6% reduction in number of sensitive bacteria), in
either case being the lowest on day 3 (Fig. 4D vs. 4C).
Quantitatively, the decrease in total E. coli matched field data;
the timing was not contrasted because in the field study available
for comparison with the scenarios SB1-SB3, the fecal samples were
only obtained on days 0, 2, 6, 9, 13, 16, 20, and 28 of therapy [84].
The fraction of resistant E. coli, however, still rose to its highest of
93% on day 3 with 4.4 mg, cf. 95% on day 4 with 6.6 mg (Fig. 4A).
The fraction reported by the field study varied from 40% to 90%
[84]. In both scenarios SB2 and SB3, it took 111-112 days for the
fraction of resistant E. coli to completely return to pre-treatment
level.
With 6.6 mg CE/kg dosage, whether this was administered
once on day 0, or 3 times on days 0, 6 and 13 (Table S1, SB1 vs.
SB2) had a very limited effect on the dynamics observed (Fig. 4A).
This is because the fraction of resistant E. coli was still high, and
the number of sensitive E. coli depressed, following the 1st dose at
the time the 2nd dose was given; similarly for doses 2 and 3. This
agreed with field observations [84].
For an adult dairy (SD1), the model outputs were similar to a
single administration of sustained-release ceftiofur formulation in
4.4 mg CE/kg dosage to a 6-mos beef (SB3).
Sensitivity of model outputs to variability in parameter
values. In the absence of immediate ceftiofur pressure, the
maintenance of a fraction of ceftiofur-resistant cells among
commensal enteric E. coli depended on the rate of in-flow and
out-flow of E. coli, the prevalence of ceftiofur resistance in the in-
flow, and the rate of transfer of blaCMY-2-carrying plasmids
between E. coli within the intestine, and, to a lesser extent, on the
rate of bacterial growth (Fig. 5B). Certain, although infrequent,
combinations of the parameters produced a largely elevated
frequency of resistance (Fig. 5A).
There were similar tendencies in the dynamics of ceftiofur-
resistant enteric E. coli under the scenarios of a 5-day treatment of
an adult dairy with a non-sustained release ceftiofur formulation in
2.2 mg CE/kg dosage (R2), and a single injection of a sustained-
release ceftiofur formulation to a 6-mos beef in 6.6 mg CE/kg
dosage (SB2) (Fig. 6). However, the median (over 500 model
simulations) peak fraction of resistant among enteric E. coli was in
the upper 70% range in the former vs. over 90% in the latter
scenario (Fig. 6A vs.6B). There was a substantial uncertainty in the
fraction of resistant E. coli, as during so after treatment, with the
explored parameter ranges (Figs. 6 and 7). The largest uncertainty
was observed on days 1 and 5 from start of therapy (Fig. 7). At
those time points the variability in both the ecology of enteric E.
coli, and in antimicrobial action of enteric ceftiofur metabolites
against E. coli contributed to the outcome. On day 1 (Fig. 8), a
higher fraction of resistance strongly correlated with a higher rate
of bacterial growth, and a lower MICs, which would correspond to
a larger kill of growing sensitive E. coli, hence a larger niche for
Figure 7. Frequency histograms for the fraction of ceftiofur-resistant among enteric E. coli on days 1, 5, 21, 35 and 90 from start of
therapy. Histograms are of 500 model simulations at each time point randomly varying parameters of bacterial ecology and pharmacodynamics. A:
A 5-day repeated ceftiofur administration to an adult dairy (frequency of resistance at start of therapy 0.7%). B: An injection of a sustained-release
ceftiofur formulation to a 6-mos beef (frequency of resistance at start of therapy 1.8%).
doi:10.1371/journal.pone.0036738.g007
Effects of Ceftiofur on Cattle Gut Commensals
PLoS ONE | www.plosone.org 11 May 2012 | Volume 7 | Issue 5 | e36738Effects of Ceftiofur on Cattle Gut Commensals
PLoS ONE | www.plosone.org 12 May 2012 | Volume 7 | Issue 5 | e36738expansion of the resistant cells, in turn ensured by the higher
growth potential. A higher fraction of resistance also correlated
with a higher MICr, i.e., a larger expansion of resistant E. coli if
these were less sensitive at the start of therapy. The importance of
individual parameters changed by day 5 when the fraction of
resistance, after reaching its maximum, was still correlated with
the pharmacodynamical parameters, but also became influenced
again by the rate of fractional replacement of enteric E. coli (Fig. 8).
By day 35, the fraction of resistance tended to settle at lower than
20%, further clustering toward lower values by day 90 (Fig. 7).
This outcome depended on the same parameters that were most
important for resistance maintenance in the absence of treatment:
the rate of horizontal transfer of blaCMY-2, the rate of in-flow and
out-flow of enteric E. coli, and the prevalence of ceftiofur-resistance
in the in-flow (Fig. 8, Days 35 and 90 vs. Fig. 5B).
Discussion
This modeling study suggested that ceftiofur-resistant commen-
sal enteric E. coli in cattle could persist between treatments. A low
but stable fraction of resistance can be maintained even if the
number of resistant E. coli grows slower than that of the sensitive
ones, when the rate of blaCMY-2 transfer in enteric E. coli is
sufficiently high or a sufficient fraction of ingested E. coli is
ceftiofur-resistant. The latter could occur if the conditions on the
farm allow for a close circulation of commensal E. coli between
cattle and their environment.
The values reported by field studies of the fraction of ceftiofur-
resistant cells among fecal E. coli in the absence of immediate
ceftiofur pressure were reproduced in the deterministic analysis
with a transfer rate for blaCMY-2-carrying plasmids of 4
23. For
individual plasmids, in vitro transfer rates are up to 2
23 [42]. In vivo
in post-weaned calves fed a donor and a recipient strain, a rate of
blaCMY-2-transconjugant generation in fecal E. coli of 2
23 has
been reported [27]. Several plasmids may be present in enteric E.
coli, and the blaCMY-2-transfer rate in vivo may be the cumulative
of those for individual plasmids. Generally, conjugation frequency
may depend on the physiological status of donor cells, phase of
growth of donor population [85], and physical conditions
[13,86,87]. As the enteric environment is E. coli’s ecological niche,
the cells are likely in normal physiological condition; this, coupling
with nutrient availability for population growth, absence of light
and favorable temperatures, may allow for the bacterial conjuga-
tion, and so plasmid transfer rate, to be at the high end of the
biological maximum [87,88].
Ceftiofur-resistant E. coli in this study were defined as cells
having a plasmid with blaCMY-2. A possibility of variability in the
degree of resistance conferred by presence of more than one copy
of the gene, or by presence of another mechanism of resistance,
and how this may be reflected in MIC-values, was not considered;
neither are such data available in experimental literature. This
complicated interpretation of the correlations of MICr with the
fraction of resistant among E. coli during therapy (Fig. 8).
The increase in absolute number of E. coli cells carrying
blaCMY-2 per g of feces during parenteral ceftiofur therapy could
lead to a higher frequency of horizontal transfer of this plasmidic
gene to the other enteric bacteria, including potential zoonotic
pathogens. However, this would require not only the donor but
also the recipient populations to be present in sufficient numbers
[89]. The numbers of ceftiofur-sensitive cells among the other
bacteria may be diminishing during therapy, similar to the
numbers of ceftiofur-sensitive E. coli. Hence, the net effect on the
frequency of blaCMY-2-transmission from E. coli to the other
bacteria would depend on the degree of sensitivity of the latter to
antimicrobial action of enteric ceftiofur metabolites. Importantly,
the only origin and spread of AMR considered here for ceftiofur
and E. coli were the a-priori presence of plasmidic blaCMY-2, and its
vertical and horizontal transfers, respectively. Other mechanisms,
e.g. resistance mediated by chromosomal genes or that due to
plasmid-mediated extended-spectrum beta-lactamases, may need
to be considered to understand AMR dynamics across the species.
Therefore, based on the current model, we could not infer what
effect ceftiofur therapy might have on inter-species spread of
blaCMY-2. Furthermore, evaluating the potential for spread of
AMR-determinants requires accounting for not only the within-
host dynamics addressed here, but also how the resistant bacteria
spread among the hosts, and between the hosts and their
environment.
This study highlighted that results of ceftiofur treatment trials
would be more informative for modeling if the data reported
would include the dynamical change in fraction of the resistant
fecal bacteria, and description of variability among individual
cattle. Frequent sampling during treatment would help with
detailing the length of time available for expansion of resistant
bacteria; continuing sampling post treatment would help with
understanding the mechanisms involved in resistance mainte-
nance. On the epidemiological side, important knowledge gaps are
details of E. coli cycling between cattle and their environment,
including the degree of replacement of enteric E. coli, the
prevalence of ceftiofur resistance in E. coli ingested by cattle, and
the rates of horizontal blaCMY-2-transfer in vivo. Absence of
publicly accessible data on the concentration and antimicrobial
activity of ceftiofur metabolites in cattle intestine during parenteral
therapy hinders more detailed research into the selective pressure
experienced by enteric bacteria. On the pharmacological side,
time-kill experiments (as opposed to experiments establishing
MIC-values) mimicking intestinal conditions are needed to
describe the pharmacodynamics of ceftiofur metabolites against
enteric bacteria.
To conclude, first, the results showed that reported low fractions
of ceftiofur-resistant commensal enteric E. coli in cattle could be
maintained without immediate ceftiofur pressure. Second, during
parenteral ceftiofur therapy there likely are antibiotically-active
drug metabolites in the large intestine, circumventing a slash in the
number of ceftiofur-sensitive enteric E. coli. These conclusions are
strongly supported by the concordance of the model outputs with
experimental data. Hence, there is a window during therapy when
ceftiofur-resistant E. coli could expand in absolute number and
relative frequency; the degree of expansion depends on the
parameters of antimicrobial action of the metabolites against E.
coli, as well as on the rates of enteric E. coli growth and
replacement. However, whether the post-treatment fraction of
resistance would remain elevated in the long-term depends on a
present combination of the parameters of bacterial ecology, the
same parameters that are important for maintenance of resistance
in the absence of ceftiofur pressure. Namely, these are the rate of
Figure 8. Significant linear correlations (p-value #0.05) between ranked-transformed values of the parameters of bacterial ecology
and pharmacodynamics and the frequency of ceftiofur-resistant among enteric E. coli on days 1, 5, 21, 35 and 90 from start of
therapy. A: A 5-day repeated ceftiofur administration to an adult dairy (frequency of resistance at start of therapy 0.7%). B: An injection of a
sustained-release ceftiofur formulation to a 6-mos beef (frequency of resistance at start of therapy 1.8%).
doi:10.1371/journal.pone.0036738.g008
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coli, which may be determined by which plasmids are present, and
the frequency of resistance in E. coli ingested by cattle, which may
be determined by the extent of E. coli circulation between cattle
and their environment.
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Table S1 Modeled scenarios of treatment of cattle with ceftiofur,
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